TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06665100: PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Sponsor: Pulmotect, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 100 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,440,600

Rescue Site Savings

+$940,800

Unlock Full NCT06665100 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06665100 Rescue Dossier →